PTPI vs. LUMO, MNPR, IMNN, ERNA, VCNX, TRAW, RDHL, AEZS, MIRA, and NRSN
Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Lumos Pharma (LUMO), Monopar Therapeutics (MNPR), Imunon (IMNN), Eterna Therapeutics (ERNA), Vaccinex (VCNX), Traws Pharma (TRAW), RedHill Biopharma (RDHL), Aeterna Zentaris (AEZS), MIRA Pharmaceuticals (MIRA), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical preparations" industry.
Petros Pharmaceuticals (NASDAQ:PTPI) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
Lumos Pharma received 33 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 77.27% of users gave Lumos Pharma an outperform vote.
Petros Pharmaceuticals has a net margin of 0.00% compared to Lumos Pharma's net margin of -2,434.69%. Petros Pharmaceuticals' return on equity of -102.32% beat Lumos Pharma's return on equity.
Petros Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 886.19%. Lumos Pharma has a consensus target price of $18.00, indicating a potential upside of 928.57%. Given Lumos Pharma's higher probable upside, analysts plainly believe Lumos Pharma is more favorable than Petros Pharmaceuticals.
In the previous week, Lumos Pharma had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 6 mentions for Lumos Pharma and 3 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.92 beat Lumos Pharma's score of 0.27 indicating that Petros Pharmaceuticals is being referred to more favorably in the media.
Petros Pharmaceuticals has higher revenue and earnings than Lumos Pharma. Lumos Pharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.0% of Lumos Pharma shares are owned by institutional investors. 36.4% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 25.4% of Lumos Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Petros Pharmaceuticals has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.
Summary
Petros Pharmaceuticals beats Lumos Pharma on 10 of the 17 factors compared between the two stocks.
Get Petros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Petros Pharmaceuticals Competitors List
Related Companies and Tools
